Glenmark begins anti-obesity drug trial
Glenmark said it would file its new anti-obesity drug for Phase I trail in May 2006 and plans to launch the drug by 2011.india Updated: Feb 13, 2006 18:15 IST
Glenmark Pharmaceuticals Ltd said on Monday that it would file its new anti-obesity drug for Phase I trail in May 2006 and plans to launch the drug by 2011.
The molecule, GRC 10389, which is presently completing pre-clinical studies for obesity and its associated disorders, is the lead candidate in the company's Cannabinoid (CB-1) receptor antagonist programme, the company informed the stock exchanges.
"CB-1 receptor antagonists are being increasingly looked at for treating obesity and Glenmark is keen on being one of the early players in this category, " the company's managing director and CEO Glenn Saldanha said.
The company expects to file the compound for a Phase I trial by May 2006 and the Phase II would follow by January 2007. It anticipates launching the product for the primary indication in the first geography by 2011 subject to success in all ensuing clinical trials.
First Published: Feb 13, 2006 18:15 IST